Loading clinical trials...

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy | Clinical Trials | Clareo Health

RECRUITINGNA

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy

An Oncology Nurse Artificial Intelligence Agent to Reduce Cancer Distress of Patients Undergoing Radiotherapy: A Mixed-Methods Randomized Controlled Trial

NCT06636188•The University of Hong Kong

View on ClinicalTrials.gov

Summary

Detailed Description

The goal of this clinical trial is to assess the effectiveness of the Digi-Coach chatbot for reducing physical and psychological distress in people undergoing radiotherapy for head and neck cancer. The main question it aims to answer is: How effective is the Digi-Coach chatbot in reducing physical and psychological distress? Researchers will compare Digi-Coach chatbot to usual nursing care to see if Digi-Coach chatbot is effective for reducing physical and psychological distress in people undergoing radiotherapy for head and neck cancer. A single-blinded parallel randomized controlled trial (RCT allocation ratio = 1:1) will be conducted, with baseline data collection at week 1 (T0) and three follow-up timepoints at week 8 (T1), week 12 (T2) following radiotherapy commencement. Participants in the Treatment-As-Usual group will receive routine onsite nursing care in which the nurse discussed general knowledge of self-care behaviors regarding the management of radiotherapy-related side effects. Participants in the intervention group will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer-related concerns in the chatbot.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•aged 18 and above
•are able to read and speak Cantonese or Mandarin fluently
•have a new, primary diagnosis of head and neck/laryngeal cancer
•are waiting to receive a full course of curative-intent, external beam radiotherapy with or without chemotherapy
•have a Karnofsky performance score ≥70
•have distress scored 3 or above on the NCCN distress thermometer

Exclusion Criteria

•insufficient command of Chinese
•have any other factors precluding the ability to give informed consent or comply with the protocol

Locations (2)

The University of Hong Kong

Hong Kong, Hong Kong, Hong Kong

Queen Mary Hospital

Hong Kong, Hong Kong, Hong Kong

Key Dates

Start Date

February 1, 2026

Primary Completion Date

November 1, 2027

Completion Date

November 1, 2028

Last Updated

March 9, 2026

Enrollment

138

ESTIMATED participants

Conditions

Head and Neck Cancer

Interventions

Digi-Coach Chatbot

OTHER

Contacts

Tongyao Wang, PhD

CONTACT

852-39102790 tongyao1@hku.hk

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Advanced Solid TumorAdvanced Malignant Neoplasm+28 more

View study

RECRUITINGPHASE2

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer

NCT07457346

Head and Neck Cancer Squamous Cell Carcinoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy

Inclusion Criteria

Exclusion Criteria

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors